Kezar Life Sciences, Inc. (NASDAQ:KZR) Major Shareholder Sells $544,800.00 in Stock

Kezar Life Sciences, Inc. (NASDAQ:KZRGet Rating) major shareholder Morningside Venture Investment sold 80,000 shares of the business’s stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $6.81, for a total transaction of $544,800.00. Following the transaction, the insider now owns 5,792,993 shares of the company’s stock, valued at approximately $39,450,282.33. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Morningside Venture Investment also recently made the following trade(s):

  • On Tuesday, January 17th, Morningside Venture Investment sold 6,114 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.79, for a total value of $41,514.06.
  • On Thursday, January 12th, Morningside Venture Investment sold 5,000 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.77, for a total transaction of $33,850.00.
  • On Thursday, January 5th, Morningside Venture Investment sold 12,162 shares of Kezar Life Sciences stock. The shares were sold at an average price of $6.97, for a total transaction of $84,769.14.

Kezar Life Sciences Trading Down 3.0 %

Shares of KZR traded down $0.21 during mid-day trading on Wednesday, hitting $6.80. 523,801 shares of the company were exchanged, compared to its average volume of 717,319. Kezar Life Sciences, Inc. has a 1-year low of $4.30 and a 1-year high of $18.55. The company has a 50 day moving average of $7.02 and a 200-day moving average of $8.29. The company has a quick ratio of 31.15, a current ratio of 31.15 and a debt-to-equity ratio of 0.03.

Kezar Life Sciences (NASDAQ:KZRGet Rating) last released its earnings results on Thursday, November 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. Equities analysts forecast that Kezar Life Sciences, Inc. will post -1.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Wells Fargo & Company cut their price target on Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating for the company in a research note on Tuesday, January 3rd.

Hedge Funds Weigh In On Kezar Life Sciences

A number of institutional investors have recently added to or reduced their stakes in KZR. Great West Life Assurance Co. Can purchased a new stake in Kezar Life Sciences in the 3rd quarter valued at $26,000. Amalgamated Bank acquired a new position in shares of Kezar Life Sciences during the 1st quarter valued at about $70,000. Tower Research Capital LLC TRC grew its holdings in shares of Kezar Life Sciences by 88.9% in the third quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company’s stock valued at $58,000 after purchasing an additional 3,190 shares during the period. Robeco Institutional Asset Management B.V. acquired a new stake in Kezar Life Sciences during the third quarter worth about $68,000. Finally, UBS Asset Management Americas Inc. purchased a new position in Kezar Life Sciences during the third quarter worth about $86,000. Hedge funds and other institutional investors own 84.03% of the company’s stock.

About Kezar Life Sciences

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.

See Also

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.